Physician in lab reading screen

Advancing the Cutting Edge of Cancer Care

While cancer care has already made tremendous progress, further innovation and research are necessary to develop and implement the next generation of therapeutics, best practices, disease preventions and specialized treatments targeted to the precise needs of the patient. Investigative research, including both “wet” translational and laboratory research as well as “dry” population health and value-based research, provides the ability to identify, develop and study new innovations in a real health system setting. The AdventHealth Cancer Institute participates in approximately 175 clinical trials each year, making it one of the most active sites for this kind of research in all of Florida.

Recent News

Physicians in surgery
Blog
Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy Can Improve Survival and Quality of Life For Certain Patients with Peritoneal Carcinomatosis
3C Board Member
Blog
Health Equity Matters
News
AdventHealth Clinical Research Unit Recruiting Patients with Solid Tumors Harboring MTAP Deletion for Phase I Clinical Trial
Karen D. Corbin, PhD, RD
Blog
Embrace the Power of Storytelling to Advance Science and Medicine
News
New England Journal of Medicine highlights Guru Sonpavde, MD’s work in new immunotherapy-chemotherapy combination improving survival for patients with advanced urothelial carcinoma

Upcoming Events

1 items. To interact with these items, press Control-Option-Shift-Right Arrow
  • GI Oncology Symposium 2024

    Details TBD

Oncology

Cancer Institute Newsletter

Read the latest from the AdventHealth Cancer Institute, including clinical innovation, peer-to-peer insights, rare cases and more.

Highlighted Cancer Trials

Through cancer trials, we hope to find new ways to improve patients’ cancer treatments and quality of life. Our clinical trials provide access to innovative and experimental therapies to patients with solid and circulating tumors, including through the National Cancer Institute’s Clinical Trials Network (NCTN). Our centralized clinical research team is comprised of research nurses, data managers, research assistants and regulatory coordinators.

View All Cancer Trials

3 items. To interact with these items, press Control-Option-Shift-Right Arrow
  • Now Enrolling

    Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPC

    Principal Investigator: Carlos Alemany, MD

  • Now Enrolling

    A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

    Principal Investigator: Mohamedtaki Tejani, MD

  • Now Enrolling

    A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 7FL)

    Principal Investigator: Carlos Alemany, MD

Hexagon Background Image
A doctor looking through a microscope

Nationally Ranked Cancer Experts

Our oncologists, surgeons and other specialists serve as principal and co-investigators for a broad array of clinical trials exploring new treatments for all types of cancer. They frequently present at national and international forums and participate in developing new diagnostic technologies, state-of-the-art surgical systems and novel cancer therapies. Learn about the physicians and learn about the latest discoveries here.